Opinion|Videos|September 4, 2024
Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors
Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Is there a specific patient population that might benefit from this treatment?
- Are there any external factors that may impact your treatment selection? Are you monitoring your patients for EBV titer?
Advertisement
Related to this article
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma
2
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
3
Dive Into Key Data and Presentations From EHA 2026
4
Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma
5